Tiziana Life Sciences Ltd
TLSA
1.06 $
1 Tag: -3.67% (-0.04 $)
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer TLSA
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Aktuelle News
-
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Vorschau anzeigen
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies. MSA is a rapidly progressive...
-
MARKETS LIVE: Wall Street closes mixed as cooling inflation lifts Nasdaq
Vorschau anzeigen
4:10pm: Mixed finish US stocks finished mixed on Wednesday, with the Nasdaq edging higher as a cooler reading on core PCE inflation gave investors some relief on the price pressures facing the economy. The Dow Jones Industrial Average fell 444 points, or 0.9%, to 50,906, while the S&P...
-
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
Vorschau anzeigen
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy (MSA). MSA i
-
Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial
Vorschau anzeigen
Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce an important milestone in the company’s neuroimmunology pipeline, with the first three participants receiving their initial doses of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial. The study is evaluating intranasal foralumab as a potential treatment for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that damages nerve cells responsible for controlling voluntary muscle movement. The BANYAN trial is sponsored by Tiziana Life Sciences and co-funded by the ALS Association through its Hoffman ALS Clinical Trial Awards Program. Elrifi said the dosing of the first participants represents an important step in advancing the clinical development of foralumab and supports Tiziana’s broader strategy of investigating therapies designed to target neuroinflammatory mechanisms that may play a role in neurological diseases. The Phase 2a study is initially being conducted at the Sean M. Healey & AMG Center for ALS at Mass General Brigham in Boston. The company expects the trial to expand to additional clinical sites, including Northwestern Medicine’s Les Turner ALS Center in Chicago, the University of Minnesota in Minneapolis and Nova Southeastern University in Florida. BANYAN is expected to enroll 44 people with early-stage ALS who meet specific clinical and biomarker criteria. Participants must have experienced symptom onset within the previous 24 months, have a slow vital capacity of at least 65%, and demonstrate elevated levels of neurofilament light chain (NfL) of 40 pg/mL or greater. Participants will be randomized in a 3-to-1 ratio to receive either intranasal foralumab or placebo during a 12-week controlled treatment period. This will be followed by a 12-week extension phase during which all participants will receive active treatment. The primary objective of the study is to assess the safety and tolerability of intranasal foralumab in people with ALS. Investigators will also evaluate a series of secondary and exploratory endpoints intended to provide additional information on the treatment’s biological activity and its potential effects on disease-related biomarkers. As enrollment and treatment continue, Tiziana expects the BANYAN study to generate additional data on the safety profile and immunological activity of intranasal foralumab in ALS patients. The company says the research could also contribute to a broader understanding of how modulation of the immune system may influence processes associated with neurodegenerative disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #ALS #AmyotrophicLateralSclerosis #Biotech #ClinicalTrials #NeurodegenerativeDisease #Neuroimmunology #DrugDevelopment #LifeSciences #HealthcareInnovation #Biotechnology #MedicalResearch #SteveDarling
-
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
Vorschau anzeigen
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral sclerosis (ALS). The Healey ALS MyMatch BANYAN trial is testing foralumab, a fully human anti-CD3...